Cytomegalovirus gastrointestinal diseases (CMV-GIDs) are end-organ diseases of the gastrointestinal (GI) tract caused by CMV in immunocompromised patients. We aimed to evaluate the performance of quantitative polymerase chain reaction (qPCR) on endoscopic biopsies. We retrospectively reviewed the qPCR data on endoscopic biopsies in nonhuman immunodeficiency virus (HIV) immunocompromised patients between January 2009 and May 2015. The performance of the qPCR for CMV-GID was evaluated with the sensitivity, specificity, and area under the receiver operating characteristic curve (AUROC). A total of 195 patients were included, and 28 patients with confirmed CMV-GID were identified. The AUROC of the qPCR was 0.935 (95% confidence interval [CI], 0.885 to 0.985), the sensitivity was 89.3% (95% CI, 71.8 to 97.7%), and the specificity was 85.6% (95% CI, 79.4 to 97.6%) with a cutoff value of 180 copies/μg DNA. The proportion of patients with inflammatory bowel disease in the histopathology-negative, PCR-positive group was smaller than that in the histopathology-positive group (10.7 vs 35.0%, p = 0.026), but other characteristics were not significantly different. The use of qPCR on endoscopic biopsies demonstrated good diagnostic performance for detecting CMV in non-HIV immunocompromised patients. It may increase the diagnostic yield when combined with a conventional histopathology.
Introduction
Cytomegalovirus gastrointestinal disease (CMV-GID) is a tissue-invasive, end-organ disease. It is a major cause of morbidity and mortality in immunocompromised patients, especially in transplant recipients and human immunodeficiency virus (HIV)-infected patients, as well as in those who receive immunosuppressive drugs [1] [2] [3] [4] [5] . A definitive diagnosis of CMV-GID requires a biopsy obtained by endoscopy with histologic or culture-based evidence of CMV [6] . However, a viral culture is not routinely performed, and the histopathology of biopsied tissue has limited sensitivity, as previously demonstrated in a study of CMV oesophagitis in HIVinfected patients, which showed three biopsy samples were diagnostic in 80% of patients, with as many as 10 biopsy samples needed for the diagnosis in the remaining patients [7] .
Noninvasive molecular diagnostic tools, such as the CMV antigenaemia assay and polymerase chain reaction (PCR) on blood samples, are widely used, although the latter is not approved in Japan. Despite the high sensitivity of the CMV antigenaemia assay for detection of viral reactivation before the onset of CMV pneumonitis in haematopoietic stem cell transplant (HSCT) recipients, this assay does not necessarily provide positive results preceding the onset of other CMV diseases [8] . For example, Jang et al. [9] reported insufficient sensitivity of the CMVantigenaemia assay for the diagnosis of CMV-GID.
Real-time quantitative PCR (qPCR) on blood samples is considered to be more sensitive than the CMV antigenaemia assay [10] . However, Mori et al. [8] reported that the blood PCR assay yielded positive results for only 50% of HSCT recipients with CMV-GID. In solid organ transplant (SOT) recipients, the sensitivity of qPCR analysis of plasma samples has been reported to be 85 to 97% in CMV-positive donor (D+ )/CMV-negative recipient (R−) patients, but it is decreased to 50 to 75% in R+ patients [11, 12] .
Tissue diagnostics, such as viral culture and tissue PCR, are expected to increase the diagnostic yield for CMV-GID. Fisher et al. [12] reported that the addition of a viral culture to histopathology increases the diagnostic yield for CMV-GID in SOT recipients. PCR on tissue samples is also a promising tool due to its short turn-around-time (TAT) and presumptive high accuracy. Burston analysed the diagnostic accuracy of a real-time qualitative PCR assay on biopsies targeting DNA polymerase for the diagnosis of CMV disease in non-HIV patients [13] . In that study, the sensitivity was 100% (95% confidence interval [CI], 79.4 to 100%), and the specificity was 71.9% (95% CI, 65.1 to 78.1%); however, various organs other than the GI tract were included, and the PCR was performed in a qualitative manner. In the latest consensus definition of CMV diseases in transplant recipients, Bpossible disease^was proposed that requires a positive result from qPCR performed on endoscopic biopsies but does not require evidence of CMV by histopathology [6] ; the optimal cutoff value remains to be determined. The objective of our study was to evaluate the diagnostic accuracy and optimal cutoff value of qPCR performed on tissue samples for diagnosing CMV-GIDs in non-HIV immunocompromised patients.
Methods

Study design
This single-centre, retrospective, cross-sectional study was approved by the Ethics Committee of Kyoto University Graduate School and the Faculty of Medicine (R0454). The need to obtain informed patient consent was waived.
Participants
The database was retrospectively reviewed to identify consecutive adult patients (aged > 18 years) whose endoscopic biopsies of the GI tract (oesophagus, stomach, small bowel, or colon) were subjected to qPCR (limited to one episode per patient) between January 2009 and May 2015 at Kyoto University Hospital, which is a 1121-bed tertiary referral hospital in Kyoto, Japan. Non-HIV immunocompromised patients, including post-transplant patients, patients with haematological malignancy, and patients receiving immunosuppressive therapy, were eligible. The index test was real-time qPCR performed on endoscopic biopsies, and the reference standard was CMV evidence in the tissue shown by histopathology or immunohistochemistry (IHC) using biopsies obtained at the same time but from a different site than that used for the PCR analysis. Patients who had a history of CMV-GID and those who did not have a concurrent histopathology examination were excluded from the study.
Definitions of CMV-GID
CMV-GID was defined as either proven, probable, or possible disease according to previously published consensus definitions of CMV disease in transplant recipients [6] . A definition of proven disease required upper and/or lower GI symptoms, macroscopic mucosal lesions, and evidence of CMV in the tissue shown by histopathology or IHC. Probable disease required upper and/or lower GI symptoms and CMV evidence in the tissue but did not require macroscopic mucosal lesions. Possible disease required upper and/or lower GI symptoms and CMV evidence based on qPCR performed on endoscopic biopsies. In this study, only patients with proven and probable disease were defined as having BCMV-GID^because in the possible disease, the index test result is included but the reference standard is not.
PCR assay
The PCR assay was performed at the discretion of the endoscopist. DNA extraction from endoscopic biopsies was performed using a QIAamp DNA Mini Kit (Qiagen, Hilden, Germany) according to the manufacturer's instructions. The typical tissue size for extraction is approximately 30 mm 3 . During the study period, 2 in-house real-time qPCR assays targeting the immediate-early (IE) genes were used at Kyoto University Hospital with the following primers and probe: forward (5′-GACTAGTGTGATGCTGGCCAAG-3′) and reverse (5′-GCTACAATAGCCTCTTCCTCATCTG-3′) primers and probe (5′-FAM-AGCCTGAGGTTATC AGTGTAATGAAGCGCC-TAMRA-3′). BLAST search was undertaken in the GenBank database (http://blast.ncbi.nlm. nih.gov/Blast.cgi) in order to ensure that the primer and probe were not homologous with other viruses. During the first period, from January 2009 to June 2010, an assay using the ABI PRISM 7700 (Thermo Fischer Scientific, Waltham, MA, USA) was performed as previously described, with modifications [14] . In the second period, from July 2010 to May 2015, real-time qPCR was performed in a 25-μL reaction volume containing 0.2 μM of forward and reverse primers, 0. 125 μM of probe, 2.5 μL of TaqMan Gold Buffer A (Thermo Fischer Scientific), and 125 ng of purified DNA. Thermal cycling was performed in a Step One Plus thermocycler (Thermo Fischer Scientific) as follows: 10 min at 95°C followed by 50 cycles of 15 s at 95°C and 1 min at 60°C. The results are reported as copies/μg DNA. The limit of detection was 10 copies/μg DNA for both assays. The linear range of both assays was 10 to 10 6 copies/μg DNA.
Statistical analysis
Descriptive statistics included counts and percentages for qualitative variables and quartiles (25th, 50th, and 75th percentile) for quantitative data. Categorical variables were compared using the Fisher exact test. Continuous variables were compared using the Mann-Whitney U test. The diagnostic accuracy of qPCR was evaluated by the area under the receiver operating characteristic curve (AUROC), and the optimal cutoff values were determined using the maximum Youden index. The sensitivity and specificity were evaluated at the cutoff value. Estimates of conditional probability were accompanied by 95% CIs. For patients with multiple specimens tested by qPCR, the maximum value reported was chosen for the analysis. A p value < 0.05 was considered statistically significant. All statistical analyses were performed with EZR (Saitama Medical Center, Jichi Medical University, Saitama, Japan), which is a graphical user interface for R (The R Foundation for Statistical Computing, Vienna, Austria). The sample size was estimated as follows: using a pre-determined value of the AUROC of 0.90, to estimate the AUROC with 95% confidence and a degree of precision of approximately 0.10, the required sample size was calculated to be at least 27 patients in each disease and non-disease group, as previously described [15] . The results of this study are reported according to the Standards for Reporting Diagnostic Accuracy Studies (STARD) statement [16] .
Results
Participants
Between January 2009 and May 2015, 516 patients from the qPCR database of the Department of Clinical Laboratory Medicine were assessed for initial eligibility and invited to participate. Figure 1 shows the flow of patients through the study. A total of 321 patients were excluded for the following reasons: 123 patients had duplicate data, 106 patients were not immunocompromised, 46 patients did not have concurrent histology, 41 patients were less than 18 years old, 3 patients had a past history of CMV-GID, 1 patient was HIV-positive, and 1 patient had insufficient data (biopsy organ was unknown). Among the 195 eligible patients, 28 patients (14.3%) with proven CMV-GID (15 of the upper GI tract and 13 of the lower GI tract), 40 patients (20.5%) with possible disease, and 127 patients (65.1%) with non-CMV-GID were identified. There were no cases of probable disease.
The baseline clinical characteristics of the patients are presented in Table 1 GID groups, the alternate diagnoses were as follows: 67 (40.1%) with ulcerative colitis, 48 (28.7%) with nonspecified GI diseases, 23 (15.6%) with graft-versus-hostdisease (GVHD), and 7 (4.2%) with drug-induced ulcers.
Diagnostic performance of qPCR on biopsies
The qPCR results are presented in Fig. 2 . Among the 28 patients with proven disease, 27 patients were qPCR-positive. To discriminate the proven group from the possible and non-CMV-GID groups, the ROC analysis produced an AUROC of 0.935 (95% CI, 0.885 to 0.985) with a sensitivity of 89.3% (95% CI, 71.8 to 97.7%) and a specificity of 85.6% (95% CI, 79.4 to 97.6%) for a cutoff value of 180 copies/μg DNA (Fig. 3) . One patient in the proven disease group had a negative qPCR result. The patient was a 60-year-old man who received immunosuppressive therapy for granulomatosis with polyangiitis and was diagnosed with CMV gastritis by histopathology. He was not using antiviral drugs. The subgroup analysis of patients without prior antiviral drug therapy resulted in an AUROC of 0.933 (95% CI, 0.864 to 1.000) with a sensitivity of 88.9% (95% CI, 65.3 to 98.6%) and a specificity of 87.2% (95% CI, 79.8 to 91.7%) for a cutoff value of 530 copies/μg DNA ( Table 2 ). The subgroup analysis based on underlying disease category is also shown in Table 2 . The cutoff value ranged from 180 to 600 copies/μg DNA, except for that of the IBD patient, which was 10,000 copies/μg DNA.
As shown in Fig. 2 , the PCR value of patients with proven disease was significantly higher than that of patients with possible disease. A significantly greater proportion of patients had IBD in the possible group (10.7 vs 35.0%, p = 0.026), and significantly higher number of blood lymphocyte count was CMV DNA qPCR copy numbers according to patient group. In the box and whisker plots, the boxes include 50% of the sample data, with the median value indicated by a horizontal bar. The whiskers include 1.5 × the interquartile range. The copy numbers of proven CMV-GID were significantly higher than those of possible CMV-GID (p < 0.001).
seen in the possible group ( 
Discussion
To the best of our knowledge, this study represents the largest cohort studied to date to evaluate the accuracy of qPCR performed on tissue samples to diagnose CMV-GIDs. The diagnostic performance of qPCR was excellent. We showed that the sensitivity of qPCR was 89.3%, which was consistent with a previous study that assessed the performance of qPCR on formalin-fixed, paraffin-embedded (FFPE) tissue [17] . That study compared results from IHC and qPCR on FFPE tissue. Although the same tissue sample was used for IHC and qPCR, 3 cases (9.1%) were found to be PCRnegative among the 33 IHC-positive cases. The authors proposed sampling error as a cause of the false negatives. In our study, 1 case of CTD was found to be PCR-negative and histopathology-positive. Sampling error was likely the cause of this result because different single biopsy samples were obtained for histopathology and qPCR. The use of multiple biopsies might have lowered the incidence of sampling error.
Although the AUROC was comparable between patients with or without prior antiviral drug treatment, the cutoff value of the former group was greater than that of the latter group. It is expected that antiviral drugs may lower the sensitivity of diagnostic tests because these drugs affect the virus-infected GI tissue, which decreases the viral load within that tissue. To evaluate the true diagnostic accuracy of qPCR, only patients without exposure to antivirals before the biopsy should be CMV-GID, cytomegalovirus gastrointestinal disease; qPCR, quantitative polymerase chain reaction; CI, confidence interval; AUROC, area under the receiver operating characteristic curve; CI, confidence interval; HSCT, haematopoietic stem cell transplant; GI, gastrointestinal; GVHD, graft-versus-host disease; SOT, solid organ transplant included, although that introduces a selection bias. It is difficult to fully exclude the effect of prior exposure to antiviral drugs on the accuracy of qPCR in diagnosing CMV-GID because in the real world, it is necessary to begin treatment without waiting for endoscopic examination, especially for transplant patients. The specificity of qPCR was 85.6%, which was also consistent with a study on FFPE tissue qPCR [17] and better than that demonstrated in a study with qualitative PCR of tissue [13] . In the guidelines for opportunistic infections in HIVinfected patients [18] , tissue diagnostics, such as viral culture, are not recommended because asymptomatic viral shedding is common in HIV patients [19] . Data on asymptomatic viral shedding in the non-HIV patients are insufficient; however, CMV reactivation is frequently observed in IBD patients [20] . In this study, the cutoff value for IBD patients was as high as 10,000 copies/μg DNA (Table 2) , which may reflect asymptomatic viral shedding, although the sample size is limited. Because IBD patients without immunosuppressive therapy were not included, further study is needed to evaluate the role of qPCR in discriminating true pathogenicity from nonspecific reactivation in IBD patients. The smaller qPCR value in the possible disease group may indicate that the viral burden differs between groups. Moreover, the difference of lymphocyte count between groups may also suggest that the risk for CMV disease differs between groups. Given a certain proportion of the patients who had been treated in the possible group had demonstrated clinical response, it is worth evaluating the possible group as a distinct category. However, the greater proportion of IBD patients in the possible group and the existence of patients who have improved without treatment may indicate the possibility of nonpathogenic viral shedding in the possible group.
Although qPCR performed on endoscopic biopsies demonstrated good sensitivity and specificity, this procedure requires an endoscopic examination, which can be invasive for patients. In situations where patients can undergo an endoscopy, if qPCR is performed routinely it is useful for early therapy due to its shorter TAT. On the other hand, if qPCR is performed when histopathology is negative, it may increase the diagnostic yield for CMV-GID by defining patients who belong to the possible group. Therefore, it is expected that clinicians can make a clinical decision to start antiviral drugs based on the result of qPCR assays.
This study had other inherent limitations. First, it was a single-centre, retrospective analysis. Second, the sample size was not large enough to achieve an accurate estimation of diagnostic values. Third, not all patients who were suspected to have CMV-GID were included because the participants of this study were reviewed using the qPCR database. Finally, the methodology for qPCR performed on tissue samples is not standardised, unlike qPCR performed on plasma, which, according to a 2010 WHO International Standard, has a more reproducible methodology across laboratories [21] . Further study is warranted to determine standardised methods for qPCR performed on tissue samples.
In conclusion, qPCR performed on endoscopic biopsies of the GI tract achieved good results for diagnosing CMV-GID in non-HIV immunocompromised patients. It also may increase the diagnostic yield when performed in combination with conventional histopathological examinations, but we have to be aware of the possibility of nonpathogenic viral shedding.
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